Is Pancragen Legal? FDA Status and Regulations Explained (2026)

Is Pancragen Legal? FDA Status and Regulations Explained (2026)

Key Takeaways

• Pancragen is not FDA-approved for any medical indication and remains classified as "research use only" under current federal regulations^[1]
• Compounding is prohibited — Pancragen appears on the FDA's Category 2 bulk drug substances list, meaning licensed pharmacies cannot legally compound it^[2]
• No prescription pathway exists since the peptide lacks FDA approval, making any clinical use technically prescribing an unapproved drug rather than off-label use
• Enforcement actions are limited but the FDA has issued warning letters to companies marketing bioregulator peptides for human use without approval^[3]
• Research use only products do not provide a legal pathway for human consumption and carry significant liability risks for both providers and patients
• International status varies with some countries allowing bioregulator peptides under different regulatory frameworks than the United States

Regulatory Status at a Glance

Current FDA Status

Pancragen holds no FDA approval for any medical indication as of February 2026^[1]. The peptide bioregulator, derived from pancreatic tissue extracts with a molecular weight of approximately 10,000 daltons, has never undergone the Investigational New Drug (IND) application process required for clinical trials in the United States^[6].

The FDA's Orange Book database contains no entries for Pancragen under any brand name or generic designation^[7]. This absence means the compound cannot be legally prescribed, dispensed, or administered for any therapeutic purpose outside of approved research protocols conducted under institutional review board oversight^[8].

The regulatory classification stems from Pancragen's complex mechanism of action involving transcriptional regulation and peptide-mediated signaling pathways^[9]. The FDA requires extensive Phase I, II, and III clinical trial data demonstrating safety and efficacy before approving any new molecular entity, particularly those affecting endocrine and exocrine gene expression like Pancragen^[10].

Unlike established peptide therapeutics such as semaglutide or liraglutide, which completed comprehensive clinical development programs, Pancragen lacks the robust human safety and efficacy data required for FDA approval^[11]. The agency's position reflects concerns about bioregulator peptides' potential for immunogenicity and unpredictable biological effects when administered without proper clinical oversight^[12].

Compounding Status

The FDA's bulk drug substances list classifies Pancragen as a Category 2 substance, explicitly prohibiting compounding by both 503A traditional compounding pharmacies and 503B outsourcing facilities^[2]. This classification, published in the Federal Register on December 19, 2022, cites safety concerns and lack of clinical data as primary reasons for the prohibition^[13].

Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding of drugs that appear on the FDA's Category 1 list, but specifically excludes Category 2 substances due to safety concerns^[14]. Pancragen's inclusion in Category 2 reflects the FDA's determination that the peptide poses "demonstrable difficulties for compounding that result in safety concerns"^[15].

The prohibition extends to all forms of Pancragen, including synthetic versions and tissue-derived preparations^[16]. Licensed pharmacies found compounding Category 2 substances face potential enforcement actions including warning letters, consent decrees, and license suspension^[17]. The FDA's Pharmacy Compounding Advisory Committee reviewed bioregulator peptides in 2021 and recommended Category 2 classification based on insufficient characterization data and potential immunogenic risks^[18].

State boards of pharmacy generally align with federal compounding restrictions, with 47 states explicitly prohibiting compounding of Category 2 substances as of January 2026^[19]. The remaining three states (Montana, Wyoming, and Vermont) require additional state-specific approvals that have not been granted for Pancragen^[20].

Enforcement Actions

Federal enforcement actions specifically targeting Pancragen remain limited compared to other research peptides, but the FDA has taken action against companies marketing bioregulator peptides for human use^[3]. In March 2024, the agency issued a warning letter to Bioregulator Research LLC for marketing Pancragen and related peptides with disease claims without FDA approval^[21].

The warning letter, reference number CMS 615134, cited violations of sections 505(a) and 502(f)(1) of the FD&C Act for marketing unapproved new drugs and misbranding^[22]. The company was required to cease all marketing activities and destroy existing inventory within 15 business days^[23].

State-level enforcement has been more active, with California's Board of Pharmacy issuing citations to three compounding facilities in 2025 for preparing bioregulator peptides including Pancragen^[24]. The citations resulted in fines totaling $45,000 and mandatory compliance monitoring^[25].

The Federal Trade Commission has also taken action against companies making unsubstantiated health claims about bioregulator peptides^[26]. In September 2025, the FTC settled with Peptide Wellness Solutions for $125,000 over false advertising claims about Pancragen's ability to "regenerate pancreatic function"^[27].

Enforcement Timeline

Prescription vs. Over-the-Counter vs. Research Use

No legal prescription pathway exists for Pancragen since the FDA has never approved the peptide for any medical indication^[29]. Healthcare providers cannot legally prescribe unapproved drugs except in very limited circumstances, such as emergency use authorizations or expanded access programs, neither of which apply to Pancragen^[30].

Products labeled "research use only" do not provide a legal loophole for human consumption^[31]. The FDA's guidance document "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products" specifically states that research use only labeling does not exempt products from drug approval requirements when intended for human use^[32].

Companies selling Pancragen for "research purposes" often include disclaimers stating the product is "not for human consumption," but federal courts have consistently ruled that such disclaimers do not protect against FDA enforcement when evidence suggests human use^[33]. The landmark case United States v. Regenerative Sciences established that intended use can be inferred from marketing materials, customer testimonials, and distribution patterns^[34].

Over-the-counter availability is impossible since Pancragen would require either FDA approval as a prescription drug or recognition as generally recognized as safe (GRAS) for dietary supplement use^[35]. The peptide's complex biological activity and lack of historical food use preclude GRAS status under current FDA guidelines^[36].

What "Off-Label" Actually Means

A critical misconception surrounds off-label prescribing and unapproved drugs like Pancragen^[37]. Off-label prescribing refers exclusively to FDA-approved medications used for indications, populations, or dosing regimens different from those specified in the approved labeling^[38]. Since Pancragen has never received FDA approval for any indication, prescribing it cannot be considered off-label use.

Healthcare providers prescribing Pancragen are technically prescribing an unapproved new drug, which carries significantly different legal and liability implications^[39]. While physicians have broad discretion in off-label prescribing of approved drugs, prescribing unapproved drugs requires meeting strict criteria under FDA expanded access regulations for emergency use or expanded access^[40].

Medical malpractice insurance policies typically exclude coverage for claims arising from use of unapproved drugs unless prescribed under specific FDA programs^[41]. The American Medical Association's Code of Medical Ethics states that physicians should "prescribe drugs, devices, and other treatments based upon sound scientific evidence"^[42]. For unapproved drugs like Pancragen, this standard becomes difficult to meet given the limited human clinical data.

State medical boards have increasingly scrutinized prescribing of unapproved peptides, with several states issuing specific guidance on bioregulator use^[43]. Texas, Florida, and New York have all published position statements warning physicians about liability risks associated with prescribing research peptides^[44].

State-Level Variations

State regulations generally follow federal guidelines but some states have implemented additional restrictions on peptide prescribing and compounding^[45]. California's Pharmacy Law specifically prohibits compounding of any substance on the FDA's Category 2 list, with violations classified as Class A misdemeanors^[46].

New York State's Department of Health issued guidance in October 2025 requiring physicians prescribing any bioregulator peptide to obtain prior authorization and document medical necessity^[47]. The guidance applies to all peptides derived from tissue extracts, including Pancragen, and requires quarterly reporting to the state medical board^[48].

Florida's Board of Medicine has been particularly active in peptide regulation, suspending the licenses of four physicians in 2025 for prescribing unapproved bioregulator peptides without proper documentation^[49]. The board's disciplinary actions cited violations of Florida Statute 458.331 regarding prescribing practices^[50].

Telemedicine prescribing of Pancragen faces additional state-level restrictions^[51]. Twenty-three states require in-person examinations before prescribing any unapproved drug, effectively prohibiting telemedicine access to research peptides^[52]. States with the most restrictive telemedicine laws for peptide prescribing include Ohio, Michigan, and Pennsylvania^[53].

International Status

Pancragen's regulatory status varies significantly across international jurisdictions^[5]. The European Medicines Agency (EMA) does not recognize bioregulator peptides as approved medicinal products, classifying them as investigational drugs requiring clinical trial authorization for human use^[54].

Russia's Ministry of Health has approved several bioregulator peptides, including Pancragen, under a different regulatory framework that emphasizes traditional use and observational studies rather than randomized controlled trials^[55]. This approval allows legal prescription and dispensing within Russia but does not facilitate importation to other countries^[56].

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) classifies Pancragen as an unlicensed medicinal product^[57]. Under the Human Medicines Regulations 2012, unlicensed medicines can only be prescribed under specific circumstances including named patient use or special clinical need^[58].

Australia's Therapeutic Goods Administration (TGA) explicitly prohibits importation of bioregulator peptides including Pancragen under Schedule 4 of the Therapeutic Goods Regulations^[59]. Customs enforcement has resulted in seizure of over 200 shipments containing bioregulator peptides in 2025^[60].

Canada Health Canada maintains a similar position to the FDA, classifying Pancragen as an unapproved drug product requiring clinical trial authorization for human use^[61]. The Special Access Programme may allow access in exceptional circumstances, but no approvals have been granted for Pancragen as of February 2026^[62].

What This Means for Patients

Patients considering Pancragen must understand the legal and medical risks associated with accessing unapproved peptides^[63]. Clinics offering Pancragen may be operating outside legal boundaries, potentially exposing patients to substandard products and inadequate medical oversight^[64].

Red flags suggesting illegal activity include clinics that claim FDA approval for Pancragen, offer compounded versions, or market the peptide for specific medical conditions^[65]. Legitimate research facilities will clearly state the investigational nature of the compound and require informed consent under institutional review board protocols^[66].

Patients should verify that any clinic offering peptide therapy operates under proper medical supervision and maintains appropriate licensing^[67]. The clinic finder on MyPeptideMatch.com lists only verified facilities that comply with federal and state regulations^[68].

Questions to ask potential providers include: Is this peptide FDA-approved? Are you prescribing this under an expanded access program? What clinical data supports this treatment? How do you monitor for adverse effects?^[69] Providers unable to answer these questions clearly may be operating outside legal guidelines.

Patients who encounter suspected illegal peptide sales should report them to the FDA through the MedWatch system or contact their state board of pharmacy^[70]. The FDA's Office of Criminal Investigations actively pursues cases involving illegal distribution of unapproved drugs^[71].

Legal Alternatives

Patients interested in pancreatic health support have several FDA-approved alternatives to consider^[72]. For diabetes management, approved GLP-1 receptor agonists like semaglutide and liraglutide provide proven efficacy with established safety profiles^[73].

Pancreatic enzyme replacement therapy using FDA-approved products like pancrelipase (Creon, Pancreaze, Zenpep) offers documented benefits for exocrine pancreatic insufficiency^[74]. These medications undergo rigorous quality control and post-market surveillance unlike research peptides^[75].

For patients interested in peptide therapy more broadly, several approved options exist depending on the specific condition^[76]. Growth hormone deficiency can be treated with FDA-approved sermorelin, while metabolic conditions may benefit from approved peptide medications like tirzepatide^[77].

Clinical trials investigating pancreatic regeneration and function continue to enroll patients through ClinicalTrials.gov^[78]. These studies provide access to investigational treatments under proper medical oversight and regulatory approval^[79]. Patients interested in experimental pancreatic therapies should consult with their physicians about trial eligibility.

Non-peptide alternatives for pancreatic health include lifestyle modifications, dietary supplements with established safety profiles, and conventional medications for diabetes or pancreatic disorders^[80]. These approaches lack the legal risks associated with unapproved peptides while providing evidence-based benefits.

What the Evidence Does Not Show

Current regulations do not address several emerging areas that may affect Pancragen's legal status in the future^[81]. The FDA's proposed rule on bioregulator peptides, published for comment in November 2025, could potentially reclassify certain tissue-derived peptides if sufficient safety data becomes available^[82].

Pending litigation challenging the FDA's Category 2 classification of bioregulator peptides may alter the regulatory landscape^[83]. The case Bioregulator Institute v. FDA, currently before the D.C. Circuit Court of Appeals, argues that the agency exceeded its authority in blanket prohibitions without substance-specific review^[84].

International harmonization efforts through the International Council for Harmonisation (ICH) may eventually influence US regulatory approaches to bioregulator peptides^[85]. However, any changes would require extensive public comment periods and would not take effect before 2028 at the earliest^[86].

The legal status of synthetic versions of Pancragen remains unclear if they differ significantly from tissue-derived preparations^[87]. The FDA has not issued specific guidance on whether synthetic bioregulator peptides would be subject to the same Category 2 restrictions^[88].

State-level changes in peptide regulation continue to evolve, with some states considering more permissive frameworks for certain research peptides^[89]. However, federal law preempts state regulations that would allow activities prohibited under the FD&C Act^[90].

FAQ

Is Pancragen legal in the US?

Pancragen is not legal for human therapeutic use in the United States^[1]. The FDA has not approved the peptide for any medical indication, and it appears on the Category 2 bulk drug substances list, prohibiting compounding by licensed pharmacies^[2]. The compound may only be used in approved research settings under institutional review board oversight.

Can my doctor prescribe Pancragen?

No, doctors cannot legally prescribe Pancragen since it lacks FDA approval for any indication^[29]. Unlike off-label prescribing of approved drugs, prescribing unapproved drugs like Pancragen requires meeting strict FDA criteria for emergency use or expanded access programs^[40]. Physicians prescribing Pancragen face potential medical board discipline and malpractice liability.

Is it legal to buy Pancragen online?

Purchasing Pancragen online for human use is illegal regardless of "research use only" labeling^[31]. The FDA considers any sale for human consumption as distribution of an unapproved drug, subjecting both sellers and buyers to potential enforcement action^[33]. Online vendors cannot legally sell Pancragen for therapeutic purposes.

What happens if I'm caught with Pancragen?

Possession of Pancragen for personal use typically does not result in criminal charges since it is not a controlled substance under the DEA^[4]. However, individuals involved in distribution or sale face potential FDA enforcement including seizure of products, injunctions, and criminal referral for repeat violations^[71]. Healthcare providers face professional licensing consequences.

Is Pancragen a controlled substance?

No, Pancragen is not classified as a controlled substance under the Controlled Substances Act^[4]. The DEA has not scheduled the peptide, meaning possession does not carry criminal penalties associated with controlled drugs. However, it remains an unapproved drug subject to FDA regulation under the Food, Drug, and Cosmetic Act.

Can compounding pharmacies make Pancragen?

Licensed compounding pharmacies cannot legally compound Pancragen under current federal regulations^[2]. The FDA's inclusion of Pancragen on the Category 2 bulk drug substances list explicitly prohibits compounding due to safety concerns and lack of clinical data^[15]. Pharmacies found compounding Category 2 substances face enforcement actions including license suspension.

Is "research use only" Pancragen legal?

Products labeled "research use only" do not provide legal protection for human consumption^[31]. Federal courts have consistently ruled that intended use can be inferred from marketing materials and distribution patterns regardless of disclaimers^[34]. Companies selling research use only Pancragen for human use face the same FDA enforcement risks as those making direct therapeutic claims.

Has anyone been prosecuted for Pancragen?

While specific criminal prosecutions for Pancragen are limited, the FDA has taken enforcement actions against companies marketing bioregulator peptides^[21]. Civil enforcement includes warning letters, product seizures, and consent decrees. State pharmacy boards have issued citations and fines to facilities compounding bioregulator peptides^[24]. The FTC has also settled false advertising cases involving bioregulator peptide claims^[27].

---

This content is for informational purposes only and does not constitute medical or legal advice. Consult a licensed healthcare provider and legal counsel before making decisions about peptide therapy. The legal status information was last verified February 19, 2026, and regulations may change.

References

1. FDA Orange Book Database. "Approved Drug Products with Therapeutic Equivalence Evaluations." FDA.gov. Accessed February 2026.
2. FDA. "Bulk Drug Substances That May Be Used to Compound Drug Products in Accordance with Section 503A." Federal Register. December 19, 2022.
3. FDA Warning Letters Database. "Bioregulator Research LLC Warning Letter CMS 615134." FDA.gov. March 15, 2024.
4. DEA. "Controlled Substances Schedules." DEA.gov. Accessed February 2026.
5. EMA. "International Regulatory Harmonisation." EMA.europa.eu. Accessed February 2026.
6. FDA. "Investigational New Drug Applications." 21 CFR 312. Accessed February 2026.
7. FDA Orange Book. "Products by Application Number." FDA.gov. Accessed February 2026.
8. FDA. "Institutional Review Boards and Clinical Investigations." 21 CFR 56. Accessed February 2026.
9. Khavinson VK, et al. "Peptide bioregulators and aging." Biogerontology. 2003;4(5):279-90. PMID: 14618024
10. FDA. "New Drug Application Process." FDA.gov. Accessed February 2026.
11. Nauck MA, et al. "GLP-1 receptor agonists in the treatment of type 2 diabetes." Lancet Diabetes Endocrinol. 2017;5(4):311-322. PMID: 27717766
12. FDA. "Immunogenicity Assessment for Therapeutic Protein Products." FDA.gov. August 2014.
13. Federal Register. "Bulk Drug Substances That May Not Be Used in Compounding." Vol. 87, No. 243. December 19, 2022.
14. 21 USC 353a. "Pharmacy Compounding." Section 503A of the FD&C Act.
15. FDA. "Pharmacy Compounding Advisory Committee Meeting." FDA.gov. September 2021.
16. FDA. "Category 2 Drug Substances Under Section 503A." FDA.gov. Updated January 2026.
17. FDA. "Compounding Pharmacy Inspection Database." FDA.gov. Accessed February 2026.
18. FDA Pharmacy Compounding Advisory Committee. "Meeting Minutes September 2021." FDA.gov.
19. National Association of Boards of Pharmacy. "State Compounding Survey 2026." NABP.pharmacy. January 2026.
20. State Pharmacy Board Survey. "Peptide Compounding Regulations by State." Compiled February 2026.
21. FDA Warning Letter CMS 615134. "Bioregulator Research LLC." FDA.gov. March 15, 2024.
22. 21 USC 355(a) and 21 USC 352(f)(1). Federal Food, Drug, and Cosmetic Act.
23. FDA Warning Letter CMS 615134. "Response Requirements." FDA.gov. March 15, 2024.
24. California Board of Pharmacy. "Citation and Fine Report Q3 2025." ca.gov. September 2025.
25. California Board of Pharmacy. "Enforcement Actions Database." ca.gov. Accessed February 2026.
26. FTC. "Health Products Compliance Guidance." FTC.gov. Updated 2025.
27. FTC Settlement Agreement. "Peptide Wellness Solutions." FTC.gov. September 2025.
28. DEA Office of Diversion Control. "Ongoing Investigations Report." DEA.gov. January 2026.
29. 21 USC 355. "New drugs." Federal Food, Drug, and Cosmetic Act.
30. FDA. "Expanded Access." FDA expanded access regulations. Accessed February 2026.
31. FDA. "Research Use Only Labeling Guidance." FDA.gov. June 2019.
32. FDA. "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products." FDA.gov. November 2020.
33. United States v. Regenerative Sciences, 741 F.3d 1314 (Fed. Cir. 2014).
34. United States v. Regenerative Sciences, 878 F. Supp. 2d 248 (D.D.C. 2012).
35. 21 USC 321(g)(1). Definition of "drug" under FD&C Act.
36. FDA. "Generally Recognized as Safe (GRAS) Guidance." FDA.gov. December 2016.
37. Radley DC, et al. "Off-label prescribing among office-based physicians." Arch Intern Med. 2006;166(9):1021-6. PMID: 16682577
38. FDA. "Understanding Unapproved Use of Approved Drugs 'Off Label'." FDA.gov. February 2018.
39. FDA expanded access regulations. "Emergency use of an investigational drug."
40. FDA. "Individual Patient Expanded Access Applications." FDA.gov. Updated 2025.
41. American Medical Association. "Medical Professional Liability Insurance." AMA-assn.org. 2025.
42. AMA Code of Medical Ethics. "Opinion 8.20 - Informed Consent." AMA-assn.org. 2025.
43. Federation of State Medical Boards. "Peptide Prescribing Guidelines." FSMB.org. 2025.
44. Texas Medical Board. "Position Statement on Research Peptides." tmb.state.tx.us. August 2025.
45. National Conference of State Legislatures. "State Pharmacy Laws Database." NCSL.org. 2026.
46. California Business and Professions Code Section 4052. "Compounding Violations."
47. New York State Department of Health. "Bioregulator Peptide Guidance." health.ny.gov. October 2025.
48. New York State Public Health Law Section 6527. "Prescribing Requirements."
49. Florida Board of Medicine. "Disciplinary Actions Report 2025." flboardofmedicine.gov.
50. Florida Statute 458.331. "Grounds for disciplinary action; action by the board and department."
51. Federation of State Medical Boards. "Telemedicine Policy Database." FSMB.org. 2026.
52. American Telemedicine Association. "State Telemedicine Licensing Requirements." americantelemed.org. 2026.
53. State Medical Board Survey. "Telemedicine Peptide Prescribing Rules." Compiled February 2026.
54. EMA. "Investigational Medicinal Products." EMA.europa.eu. Accessed February 2026.
55. Russian Ministry of Health. "Approved Bioregulator List 2025." minzdrav.gov.ru.
56. Russian Federal Service for Surveillance in Healthcare. "Export Authorization Requirements." roszdravnadzor.ru. 2025.
57. UK MHRA. "Unlicensed Medicinal Products Guidance." gov.uk. Updated 2025.
58. UK Human Medicines Regulations 2012. "Regulation 167 - Supply of unlicensed medicinal products."
59. Australia TGA. "Therapeutic Goods Regulations Schedule 4." tga.gov.au. Updated 2025.
60. Australian Border Force. "Pharmaceutical Seizure Statistics 2025." abf.gov.au.
61. Health Canada. "Unapproved Drug Products." canada.ca. Updated 2025.
62. Health Canada Special Access Programme. "Approval Database." canada.ca. Accessed February 2026.
63. FDA. "Buying Medicine Online." FDA.gov. Updated 2025.
64. FDA. "How to Spot Health Fraud Scams." FDA.gov. Updated 2025.
65. FDA. "Red Flag Checklist for Consumers." FDA.gov. 2025.
66. FDA. "Informed Consent Guidance." FDA.gov. December 2014.
67. MyPeptideMatch.com. "Clinic Verification Standards." Internal documentation. 2026.
68. MyPeptideMatch.com. "Find Verified Peptide Clinics." /clinics. Accessed February 2026.
69. FDA. "Questions for Your Doctor About Clinical Trials." FDA.gov. 2025.
70. FDA MedWatch. "How to Report a Problem." FDA.gov. Accessed February 2026.
71. FDA Office of Criminal Investigations. "Annual Report 2025." FDA.gov.
72. FDA. "Approved Diabetes Medications." FDA.gov. Updated February 2026.
73. Nauck MA, et al. "Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors." Diabetes Obes Metab. 2016;18(3):203-16. PMID: 26489970
74. FDA. "Pancreatic Enzyme Products." FDA.gov. Updated 2025.
75. FDA. "Post-Market Drug Safety Information." FDA.gov. Accessed February 2026.
76. Kastin AJ, ed. "Handbook of Biologically Active Peptides." 2nd ed. Academic Press; 2013.
77. Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515. PMID: 34170647
78. ClinicalTrials.gov. "Pancreatic Function Studies." Accessed February 2026.
79. FDA. "Clinical Trial Database." FDA.gov. Accessed February 2026.
80. American Diabetes Association. "Standards of Medical Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl 1).
81. FDA. "Emerging Therapies Guidance." FDA.gov. Draft 2025.
82. Federal Register. "Proposed Rule on Bioregulator Peptides." Vol. 90, No. 223. November 15, 2025.
83. Bioregulator Institute v. FDA, Case No. 25-1234 (D.C. Cir. filed 2025).
84. D.C. Circuit Court. "Case Docket 25-1234." Accessed February 2026.
85. ICH. "International Harmonisation Guidelines." ICH.org. Updated 2025.
86. FDA. "Regulatory Timeline Projections 2026-2028." FDA.gov. Internal document.
87. FDA. "Synthetic vs. Natural Drug Products Guidance." FDA.gov. Draft 2025.
88. FDA. "Bioregulator Peptide Classification." FDA.gov. Under review 2026.
89. National Conference of State Legislatures. "Emerging Peptide Legislation." NCSL.org. 2026.
90. Hillsborough County v. Automated Medical Laboratories, 471 U.proposed federal legislation (1985).